|
Experts assess how patent expiry of semaglutide is reshaping GLP-1 pricing and patient access
|
|
Shardul Nautiyal, Mumbai
April 08 , 2026
|
|
|
India is experiencing a rapid transformation in access to GLP-1 (glucagon-like peptide-1) receptor agonists, particularly semaglutide (the active ingredient in Novo Nordisk's Ozempic for diabetes and Wegovy for weight management). The key trigger is that the Indian patent on semaglutide expired on March 20, 2026, unleashing a flood of affordable branded generics from domestic manufacturers.
This event marks a potential turning point for pricing, patient access, and the broader GLP-1 market, not just in India, but with ripple effects globally as Indian firms eye exports.
GLP-1 receptor agonists are a class of medications that mimic a natural intestine hormone to manage type 2 diabetes and obesity. They work by stimulating insulin release, reducing glucagon, slowing gastric emptying, and promoting satiety.
The patent expiry and immediate generic surge in India's fiercely competitive generic pharma industry wasted no time. Within days of expiry (starting March 21, 2026), over a dozen major players and dozens more smaller ones launched versions of semaglutide. Around 50 branded generics from 40+ companies are available in the market.
Key early launches include Natco Pharma: Vial at Rs. 1,290 (USD 14) per month (one of the lowest); pen expected Rs. 4,000 to Rs. 4,500. Sun Pharma: As low as Rs. 750 weekly (Rs. 3,400 monthly) for some formulations. Dr. Reddy’s: Obeda (pen) at Rs. 4,200 monthly; plans for international expansion. Glenmark: GLIPIQ vials starting Rs. 325 to Rs. 440 weekly (Rs. 1,300–1,760 monthly). Others (Alkem, Zydus, etc.): Monthly costs ranging Rs. 1,800 to Rs. 4,200, with some weekly options under Rs. 1,000 to Rs. 2,000.
These represent 70–90% discounts compared to Novo Nordisk's pre-expiry prices in India (Ozempic at Rs. 8,800 to Rs. 10,000 monthly; Wegovy higher, up to Rs. 10,000 to Rs. 16,000 depending on dose).
Vial formats (multi-dose) are especially cheap but require more patient handling; pre-filled pens cost more but are more convenient. Novo responded earlier by cutting prices, launching in India (late 2025), and partnering with local firms (e.g., Abbott for Extensior/Ozempic) to defend share, especially in tier-2/3 cities.
This matters to India now, as India's massive patient burden Vikas Nim, a pharma industry expert, stated that India has 100 to 135 million people with type 2 diabetes (among the highest globally). 250+ million overweight or obese individuals.
GLP-1 drugs like semaglutide improve glycaemic control, promote significant weight loss, and offer cardiovascular benefits. Pre-generic, high prices limited uptake, doctors noted many patients could benefit, but only a small fraction used them. Sales of GLP-1s were already surging (e.g., +178% year-over-year to Rs. 14.5 billion by early 2026).
Nim stated that with prices crashing, market project explosive growth. Current GLP-1 market in India: Rs. 1,000 to Rs. 1,200 crore (USD 120 to USD 140 million) in 2025. As per Nim projections of Rs. 4,500 to Rs. 12,000 crore (USD 0.5 to USD 1.4 billion+) in 5 years are expected as sales, Moreover, penetration even at 2% of the obese population could drive billions in sales.
Turning points for pricing, access and affordability are that monthly costs could settle in the Rs. 1,500 to Rs. 5,000 range long-term (or lower with vials), making therapy viable for middle-class and some lower-income patients out-of-pocket (these drugs aren't yet widely covered by public schemes or essential medicines lists).
While adding information on the challenges Nim stated, semaglutide may be misused and carry side effects. Doctors warn against off-label lifestyle use without supervision. Risks include gastrointestinal issues, muscle loss, nutritional deficiencies, and potential long-term unknowns. It is not a "magic shortcut." Long-term use requires medical oversight. Affordability alone doesn't solve obesity's root causes (diet, exercise). Even reduced prices may strain rural/lower-income households as a share of income.
Nim states that India's model is a rapid generic entry post-patent market and could influence other markets where semaglutide patents expire soon (e.g., Canada, China, Brazil, Turkey). Indian firms like Dr Reddy’s are already planning exports.
This accelerates the shift of GLP-1s from niche/high-cost therapies to more mainstream chronic care tools. It pressures originators like Novo and Eli Lilly (whose tirzepatide/Mounjaro also gained traction in India) to innovate further (e.g., orals, combinations) or compete on value.
India's "pharmacy of the world" status positions it as a GLP-1 manufacturing hub, potentially lowering costs elsewhere while boosting domestic pharma revenues and exports. Overall, the semaglutide boom represents a rare convergence Nim states, a high-burden disease population, world-class generic manufacturing, and patent expiry creating genuine potential for scaled access. Success will depend on balanced regulation, responsible prescribing, and addressing obesity holistically, not just pharmacologically. The coming months will reveal how deeply this penetrates and whether it truly reshapes public health outcomes in India.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|